For the year ending 2025-12-31, ENZN has $42,813K in assets. $42,574K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 42,574 | |||
| Other current assets | 239 | |||
| Total current assets | 42,813 | |||
| Total assets | 42,813 | |||
| Accounts payable | 331 | |||
| Accrued expenses and other current liabilities | 400 | |||
| Total current liabilities | 731 | |||
| Series c preferred stock - 0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value 1,115 per share and 1,062 per share) at december 31, 2025 and 2024, respectively-Series CPreferred Stock | 44,607 | |||
| Common stock - 0.01 par value, authorized 170,000,000 shares issued and outstanding 74,214,603 shares at december 31, 2025 and 2024 | 742 | |||
| Additional paid-in capital | 70,034 | |||
| Accumulated deficit | -73,301 | |||
| Total stockholders' (deficit) equity | -2,525 | |||
| Total liabilities, mezzanine equity and stockholders' (deficit) equity | 42,813 | |||
ENZON PHARMACEUTICALS, INC. (ENZN)
ENZON PHARMACEUTICALS, INC. (ENZN)